Broadfin Capital’s Agreement with Nevro Corp.


Olshan advised Broadfin Capital on the negotiation

Broadfin Capital reached an agreement with Nevro Corp. for Leadership Changes and Board Representation.

Pursuant to the agreement, Rami Elghandour stepped down as Nevro’s President, CEO and a director, and D. Keith Grossman was appointed as the company’s President, CEO and a director, effective immediately.

Two new independent directors, Bess Weatherman and Kevin O’Boyle, were also appointed to Nevro’s Board and a second incumbent director also resigned from the Board.

Nevro Corp., led by D Keith Grossman, Andrew H Galligan and David Caraway operates as a medical device company focused on providing products for patients suffering from debilitating chronic pain. The company, in 2018, recorded $387 million revenues.

Olshan advised Broadfin Capital with a team including Steve Wolosky (Picture), Ryan Nebel and Ian Engoron.

Involved fees earner: Ryan Nebel – Olshan Frome Wolosky LLP; Steve Wolosky – Olshan Frome Wolosky LLP;

Law Firms: Olshan Frome Wolosky LLP;

Clients: Broadfin Capital, LLC;

Author: Ambrogio Visconti